{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:17:39Z","timestamp":1790713059978,"version":"4.1.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["Nos. 72074218"],"award-info":[{"award-number":["Nos. 72074218"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Extended-spectrum \u03b2-lactamase (ESBL)-producing Enterobacteriaceae pose a huge threat to human health, especially in the context of complicated urinary tract infections (cUTIs). Carbapenems and piperacillin\u2013tazobactam (PTZ) are two antimicrobial agents commonly used to treat cUTIs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A monocentric retrospective cohort study focused on the treatment of cUTIs in adults was conducted from January 2019 to November 2021. Patients with a positive urine culture strain yielding \u2265 103 colony-forming units per milliliter (CFU\/mL), and sensitive to PTZ and carbapenems, were included. The primary endpoint was clinical success after antibiotic therapy. The secondary endpoint included rehospitalization and 90-day recurrence of cUTIs caused by ESBL-producing Enterobacteriaceae.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 195 patients included in this study, 110 were treated with PTZ while 85 were administered meropenem. The rate of clinical cure was similar between the PTZ and meropenem groups (80% vs. 78.8%, p = 0.84). However, the PTZ group had a lower duration of total antibiotic use (6 vs. 9; p &amp;lt; 0.01), lower duration of effective antibiotic therapy (6 vs. 8; p &amp;lt; 0.01), and lower duration of hospitalization (16 vs. 22; p &amp;lt; 0.01).<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>In terms of adverse events, the safety of PTZ was higher than that of meropenem in the treatment of cUTIs.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2023.1093842","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T05:24:02Z","timestamp":1683091442000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and safety of piperacillin\u2013tazobactam compared with meropenem in treating complicated urinary tract infections including acute pyelonephritis due to extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae"],"prefix":"10.3389","volume":"13","author":[{"given":"Wei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Yu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Ting","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Shan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Yuan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.001462","article-title":"JMM profile: Carbapenems: a broad-spectrum antibiotic","volume":"70","author":"Armstrong","year":"2021","journal-title":"J. Med. Microbiol."},{"key":"B2","volume-title":"Framework for FDA\u2019s real-world evidence program","year":"2018"},{"key":"B3","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2165\/00003495-200868060-00006","article-title":"Meropenem: a review of its use in the treatment of serious bacterial infections","volume":"68","author":"Baldwin","year":"2008","journal-title":"Drugs"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a025247","article-title":"\u03b2-lactams and \u03b2-lactamase inhibitors: An overview","volume":"6","author":"Bush","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.2174\/2589977513666211206100749","article-title":"Cefiderocol- a new antimicrobial for complicated urinary tract infection (CUTI) caused by carbapenem resistant enterobacteriaceae (CRE)","volume":"14","author":"Chatterjee","year":"2021","journal-title":"Curr. Drug Res. Rev"},{"key":"B6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/14787210.2018.1429912","article-title":"Novel \u03b2-lactam\/\u03b2-lactamase inhibitors versus alternative antibiotics for the treatment of complicated intra-abdominal infection and complicated urinary tract infection: A meta-analysis of randomized controlled trials","volume":"16","author":"Chen","year":"2018","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"B7","volume-title":"Performance standards for antimicrobial susceptibility testing, M100","year":"2021"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2021.106361","article-title":"Temocillin versus carbapenems for urinary tract infection due to ESBL-producing enterobacteriaceae: A multicenter matched case-control study","volume":"58","author":"Delory","year":"2021","journal-title":"Int. J. Antimicrob. Agents."},{"key":"B9","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1128\/CMR.00037-09","article-title":"Three decades of beta-lactamase inhibitors","volume":"23","author":"Drawz","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa480","article-title":"Efficacy and safety of carbapenems vs new antibiotics for treatment of adult patients with complicated urinary tract infections: A systematic review and meta-analysis","volume":"9","author":"Ezure","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"B11","article-title":"Complicated urinary tract infections: Developing drugs for treatment guidance for industry","year":"2018"},{"key":"B12","volume-title":"SWAB guidelines for antimicrobial therapy of complicated urinary tract infections in adults","author":"Geerlings","year":"2013"},{"key":"B13","doi-asserted-by":"publisher","first-page":"106521","DOI":"10.1016\/j.ijantimicag.2022.106521","article-title":"Non-susceptibilities to antibiotics against important gram-negative bacteria, and imipenem-relebactam, meropenem-vaborbactam against carbapenem non-susceptible enterobacterales and pseudomonas aeruginosa isolates implicated in complicated intra-abdominal","author":"Jean","year":"2022","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2018.33.e213","article-title":"Real-world evidence versus randomized controlled trial: Clinical research based on electronic medical records","volume":"33","author":"Kim","year":"2018","journal-title":"J. Korean Med. Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.ijantimicag.2019.06.008","article-title":"Cost-effectiveness analysis of ceftazidime\/avibactam compared to imipenem as empirical treatment for complicated urinary tract infections","volume":"54","author":"Kongnakorn","year":"2019","journal-title":"Int. J. Antimicrob. Agents."},{"key":"B16","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40121-021-00570-z","article-title":"Aminoglycoside or polymyxin monotherapy for treating complicated urinary tract infections caused by extensively drug-resistant pseudomonas aeruginosa: A propensity score-adjusted and matched cohort study","volume":"11","author":"L\u00f3pez Montesinos","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0924-8579(00)00168-0","article-title":"Complicated urinary tract infections","volume":"15","author":"Melekos","year":"2000","journal-title":"Int. J. Antimicrob. Agents."},{"key":"B18","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ijantimicag.2018.04.001","article-title":"Molecular \u03b2-lactamase characterization of gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resis","volume":"52","author":"Mendes","year":"2018","journal-title":"Int. J. Antimicrob. Agents."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1093\/jac\/dky124","article-title":"Efficacy and safety of ceftazidime\/avibactam: a systematic review and meta-analysis","volume":"73","author":"Sternbach","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1007\/s40265-021-01580-4","article-title":"Cefiderocol: A review in serious gram-negative bacterial infections","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-020251","article-title":"Cost of hospitalised patients due to complicated urinary tract infections: A retrospective observational study in countries with high prevalence of multidrug-resistant gram-negative bacteria: The COMBACTE-MAGNET, RESCUING study","volume":"8","author":"Vallejo-Torres","year":"2018","journal-title":"BMJ Open"},{"key":"B22","article-title":"Framework for FDA\u2019s real-world evidence program","year":"2018"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab620","article-title":"Fosfomycin vs ertapenem for outpatient treatment of complicated urinary tract infections: A multicenter, retrospective cohort study","volume":"9","author":"Wald-Dickler","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2165\/00003495-199550010-00007","article-title":"Meropenem. a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy","volume":"50","author":"Wiseman","year":"1995","journal-title":"Drugs."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.2165\/00003495-200767070-00006","article-title":"Comparative review of the carbapenems","volume":"67","author":"Zhanel","year":"2007","journal-title":"Drugs."},{"key":"B26","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ijantimicag.2018.07.004","article-title":"Evaluation of the efficacy and safety of ceftazidime\/avibactam in the treatment of gram-negative bacterial infections: A systematic review and meta-analysis","volume":"52","author":"Zhong","year":"2018","journal-title":"Int. J. Antimicrob. Agents."},{"key":"B27","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12879-021-05842-0","article-title":"Multiple antimicrobial resistance and outcomes among hospitalized patients with complicated urinary tract infections in the US, 2013-2018: A retrospective cohort study","volume":"21","author":"Zilberberg","year":"2021","journal-title":"BMC Infect. Dis."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab591","article-title":"Descriptive epidemiology and outcomes of hospitalizations with complicated urinary tract infections in the united states, 2018","volume":"9","author":"Zilberberg","year":"2022","journal-title":"Open Forum Infect. Dis."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1093842\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T05:24:06Z","timestamp":1683091446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1093842\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,3]]},"references-count":28,"alternative-id":["10.3389\/fcimb.2023.1093842"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2023.1093842","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,3]]},"article-number":"1093842"}}